The Cooper Companies, Inc. (COO) is a leading global medical device company based in San Ramon, California, operating via its two core business units. Through CooperVision, the company offers an extensive portfolio of contact lenses – from daily disposables to toric and multifocal lenses – catering to vision needs like astigmatism, myopia, and presbyopia.

Meanwhile, its CooperSurgical division specializes in women’s health, providing cutting-edge solutions in fertility, obstetrics, gynecology, and genomics. Valued at $15 billion by market capitalization, Cooper stands as a healthcare innovator, driving advancements in eye care and women’s health, with a strong footprint in the medical instruments and supplies segment worldwide.

In terms of its price performance, shares of Cooper Companies have markedly trailed behind both the broader market and its industry peers. COO declined 18.2% on a year-to-date (YTD) basis, in stark contrast to the 10% gain of the S&P 500 Index ($SPX). Over the past 52 weeks, the stock dipped 20.1%, trailing the SPX’s 16.1% gains over the same stretch.

Narrowing the focus, the SPDR S&P Health Care Equipment ETF (XHE), representing the broader medical equipment segment, has also been on a downward twirl with a 5.8% decline on a YTD basis and 3.8% over the past year. However, these drops are far less severe compared to the COO’s steep declines.

Cooper Companies posted a decent fiscal second quarter on May 29, with non-GAAP EPS climbing 14% year-over-year (YoY) to $0.96 and revenue up 6% annually to $1 billion, fueled by steady organic expansion. Yet, the upbeat numbers failed to lift investor sentiment. The company’s decision to revise its full-year organic growth guidance down to a 5% to 6% range from the earlier 6% to 8% range dampened market confidence.

Coupled with tariff pressures and persistent supply chain challenges, these factors have overshadowed the company’s operational progress, keeping investors cautious and weighing heavily on the stock’s recent performance.

For the current fiscal year, ending in October 2025, analysts expect Cooper Companies to report EPS growth of 10% YoY to $4.06, on a diluted basis. The company has an impressive earnings surprise history. It has topped the Street’s bottom-line estimates in three of the past four quarters, while matching on one.

The consensus rating for the stock is a “Moderate Buy.” Out of the 16 analysts covering COO stock, 10 recommend a “Strong Buy,” one advises a “Moderate Buy,” and the remaining five analysts have a “Hold” rating.

The current setup remains fairly steady, though sentiment has eased somewhat compared to three months ago, with “Strong Buy” ratings dipping from 11 to 10, and one analyst favoring the stock but with caution, giving a “Moderate Buy” rating. 

The mean price target of $92.93 represents a premium of 23.5% to the COO’s current price. The Street-high price target of $105 suggests an upside potential of 39.6%.